Insider Selling: Alexion Pharmaceuticals Director Sells 30,000 Shares of Stock (ALXN)
Alexion Pharmaceuticals (NASDAQ:ALXN) Director Joseph Madri sold 30,000 shares of Alexion Pharmaceuticals stock on the open market in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $115.00, for a total transaction of $3,450,000.00. Following the completion of the transaction, the director now directly owns 179,217 shares of the company’s stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
A number of analysts have recently weighed in on ALXN shares. Analysts at Goldman Sachs Group Inc. raised their price target on shares of Alexion Pharmaceuticals (NASDAQ:ALXN) from $122.00 to $139.00 in a research note to investors on Wednesday. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Alexion Pharmaceuticals (NASDAQ:ALXN) in a research note to investors on Thursday, August 15th. They now have a $115.00 price target on the stock. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Alexion Pharmaceuticals (NASDAQ:ALXN) in a research note to investors on Tuesday, July 30th. They now have a $116.00 price target on the stock.
One analyst has rated the stock with a sell rating, six have given a hold rating and eleven have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $118.18.
Alexion Pharmaceuticals (NASDAQ:ALXN) traded up 1.48% on Wednesday, hitting $115.932. The stock had a trading volume of 837,161 shares. Alexion Pharmaceuticals has a 52 week low of $81.82 and a 52 week high of $125.65. The stock’s 50-day moving average is $111.1 and its 200-day moving average is $100.8. The company has a market cap of $22.671 billion and a P/E ratio of 65.13.
Alexion Pharmaceuticals (NASDAQ:ALXN) last released its earnings data on Thursday, July 25th. The company reported $0.73 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.68 by $0.05. The company had revenue of $370.10 million for the quarter, compared to the consensus estimate of $364.80 million. During the same quarter in the prior year, the company posted $0.47 earnings per share. The company’s quarterly revenue was up 34.7% on a year-over-year basis. Analysts expect that Alexion Pharmaceuticals will post $3.04 EPS for the current fiscal year.
Alexion Pharmaceuticals, Inc (NASDAQ:ALXN) is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.